Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Phase 2

Not yet recruiting

• Conditions: Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
• Interventions: Drug: Glumetinib Tablets; Drug: Docetaxel for Injection (Albumin-bound)

• Registration Number: NCT06947291
• Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Brief Summary

The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-21
• Study First Submitted QC: 2025-04-25
• Last Update Submitted: 2025-04-25
• Study First Posted: 2025-04-27
• Last Update Posted: 2025-04-27
• Study Start: 2025-04-30
• Primary Completion: 2027-04-30
• Study Completion: 2027-10-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

• 1. Patients who are able to understand and voluntarily sign the written ICF;
• 2. Male or female patients aged ≥ 18 years (inclusive);
• 3. Patients with advanced solid tumors diagnosed by pathology or cytology;
• 4. Patients with a past medical history showing either negative or positive Her-2 expression can be enrolled. For those with unknown Her-2 expression, the Her-2 status needs to be determined before enrollment. For patients with positive Her-2 expression, their previous treatments should include anti-Her-2 drug therapy.
• 5. Overexpression and/or amplification of MET in tumor tissue specimens/blood samples confirmed by the central laboratory.
• 6. There are measurable lesions or non-measurable but evaluable lesions according to RECIST v1.1.
• 7. The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score is 0 or 1.
• 8. The expected survival time is ≥ 3 months.
• 9. The functions of major organs and bone marrow meet the criteria.

Exclusion Criteria

• 1. Patients with prior treatment with targeted MET drugs;
• 2. Previous treatments included docetaxel;
• 3. Patients with meningeal metastases, spinal cord compression, symptomatic or progressive brain metastases are not eligible for enrollment.
• 4. Known hypersensitivity or intolerable conditions to any component of the drugs in the study protocol or their excipients.
• 5. According to NCI-CTCAE 5.0, adverse events caused by previous anti-tumor treatment have not recovered to ≤ Grade 1 (excluding toxicities such as Grade 2 alopecia which are judged by the investigator to pose no safety risk).
• 6. Any severe and/or uncontrolled co-existing diseases that may prevent the patient from participating in the study.
• 7. Female patients who are lactating or pregnant; Women of childbearing potential with a positive blood pregnancy test result within 7 days before trial enrollment. Lactating women can participate in this study if they stop breastfeeding, but they must not resume breastfeeding during and after the completion of the study treatment.
• 8. Any male or female patient of childbearing potential who refuses to use a highly effective contraceptive method throughout the trial period and within 6 months after the last administration.
• 9. Those who are unwilling or unable to comply with the study procedures and requirements, or those who, in the judgment of the investigator, are not suitable for participating in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Glumetinib combined with Docetaxel for Injection (Albumin-bound)	Glumetinib Tablets	Patients will be administered glumetinib once daily and Docetaxel for Injection (Albumin-bound) by intravenous injection in each 21-day treatment cycle. The treatment will continue until PD, death, intolerable toxicity, or withdrawal at the patient's discretion (whichever occurs first).
Glumetinib combined with Docetaxel for Injection (Albumin-bound)	Docetaxel for Injection (Albumin-bound)	Patients will be administered glumetinib once daily and Docetaxel for Injection (Albumin-bound) by intravenous injection in each 21-day treatment cycle. The treatment will continue until PD, death, intolerable toxicity, or withdrawal at the patient's discretion (whichever occurs first).
Glumetinib	Glumetinib Tablets	Patients will be administered glumetinib once daily in each 21-day treatment cycle. The treatment will continue until PD, death, intolerable toxicity, or withdrawal at the patient's discretion (whichever occurs first).

Primary Outcome Measures

Name	Time	Method
Dose escalation and cohort expansion phase: The occurrence and frequency of DLT (Dose-Limiting Toxicity)	Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Recommended Phase 2 Dose (RP2D) for the combination therapy.	Up to approximately 24 months after the first patient is enrolled
Proof-of-concept phase: Objective Response Rate (ORR) evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria.	Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: the occurrence and frequency of AE (Adverse Events) and SAE (Serious Adverse Events) (in accordance with NCI-CTCAE 5.0)	Up to approximately 24 months after the first patient is enrolled

Secondary Outcome Measures

Name	Time	Method
Dose escalation and cohort expansion phase: Evaluated by the Investigator according to the RECIST 1.1 criteria: Objective Response Rate (ORR)	Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Evaluated by the Investigator according to the RECIST 1.1 criteria: Disease Control Rate (DCR)	Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Evaluated by the Investigator according to the RECIST 1.1 criteria: Duration of Response (DoR)	Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria:Duration of Response (DoR)	Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Investigator according to the RECIST 1.1 criteria: Duration of Response (DoR)	Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study： Evaluated by the Investigator according to the RECIST 1.1 criteria: Progression-Free Survival (PFS)	Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study： Overall Survival (OS)	Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria: Disease Control Rate (DCR)	Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria: Progression-Free Survival (PFS)	Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study： Evaluated by the Investigator according to the RECIST 1.1 criteria: Objective Response Rate (ORR)	Up to approximately 24 months after the first patient is enrolled
Proof-of-concept study：Evaluated by the Investigator according to the RECIST 1.1 criteria: Disease Control Rate (DCR)	Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Evaluated by the Investigator according to the RECIST 1.1 criteria: Progression-Free Survival (PFS)	Up to approximately 24 months after the first patient is enrolled
Dose escalation and cohort expansion phase: Overall Survival (OS)	Up to approximately 24 months after the first patient is enrolled